UPDATE - May 21, 2024:

The CAA Research Program at MGH is excited to announce an upcoming treatment trial for patients with CAA. The trial’s short name is cAPPricorn-1 and the study drug being tested is known as “ALN-APP”. cAPPricorn-1 is sponsored by Alnylam Pharmaceuticals and is expected to launch at MGH in the fall of 2024. Additional information may be found at https://clinicaltrials.gov/study/NCT06393712.

We will share updates and further information about the study’s eligibility criteria and procedures as trial start-up progresses.

If you would like to kept apprised of this and other research opportunities for patients with CAA, please consider joining the CAA Research Recruitment Registry (“CAAR3”).

Ongoing research goals in CAA:

• To develop improved diagnostic techniques for detecting CAA

• To predict which patients with CAA are at risk for stroke recurrences after they recover from their first stroke

• To identify treatments that can substantially lower the risk for stroke recurrence in CAA